Current Smoking is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration

Abstract

Introduction: In this study, the risk factors that may influence visual improvement after intravitreal ranibizumab (IVR) treatment for exudative age-related macular degeneration (AMD) were examined.

Patients and Methods: From April 2008 to February 2012, 420 patients (448 eyes) with exudative AMD were prospectively registered at Seoul National University Hospital. From this group of patients, 125 eyes were included in this study. All patients were treated with 3 consecutive IVR injections. The best-corrected visual acuity (VA) was evaluated at baseline and 1 month after the third ranibizumab injection. To evaluate the risk factors associated with VA improvement after IVR, patient demographic data and systemic risk factors were analyzed. Patients were divided into a nonresponder group and a responder group, with reference to the median visual improvement in all eyes.

Results: Among 125 eyes, 66 eyes (52.8%) were included in the responder group and 59 eyes (47.2%) in the non-responder group. The median VA improvement after 3 monthly ranibizumab injections was -0.05 logMAR. Multivariate analyses revealed that current smoking (adjusted OR, 7.540

95% CI, 1.732–32.823) was independently associated with poor VA improvement after IVR treatment for exudative AMD.

Conclusion: Cigarette smoking is an independent risk factor for lower VA gains with IVR treatment for exudative AMD. Therefore, we believe that smoking cessation is important for a better visual outcome in AMD patients who are current smokers.